234 related articles for article (PubMed ID: 31077069)
21. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
Zhong G; Li HK; Shan T; Zhang N
Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216
[TBL] [Abstract][Full Text] [Related]
22. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Zhang Z; Jiang C; Hu L
Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
[TBL] [Abstract][Full Text] [Related]
23. [Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
Cui Y; Li J; Cao YH; Liu MY; Shi ZX; Gao TH
Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):195-200. PubMed ID: 28316218
[No Abstract] [Full Text] [Related]
24. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.
Wei J; Zou Z; Qian X; Ding Y; Xie L; Sanchez JJ; Zhao Y; Feng J; Ling Y; Liu Y; Yu L; Rosell R; Liu B
Br J Cancer; 2008 Apr; 98(8):1398-402. PubMed ID: 18362936
[TBL] [Abstract][Full Text] [Related]
25. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Jeong SH; Han JH; Kim JH; Ahn MS; Hwang YH; Lee HW; Kang SY; Park JS; Choi JH; Lee KJ; Sheen SS; Lim HY
Dig Dis Sci; 2011 Jan; 56(1):131-8. PubMed ID: 20503071
[TBL] [Abstract][Full Text] [Related]
26. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Yamada Y; Boku N; Nishina T; Yamaguchi K; Denda T; Tsuji A; Hamamoto Y; Konishi K; Tsuji Y; Amagai K; Ohkawa S; Fujita Y; Nishisaki H; Kawai H; Takashima A; Mizusawa J; Nakamura K; Ohtsu A
Ann Oncol; 2013 Oct; 24(10):2560-2565. PubMed ID: 23884439
[TBL] [Abstract][Full Text] [Related]
27. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
[TBL] [Abstract][Full Text] [Related]
29. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
[TBL] [Abstract][Full Text] [Related]
30. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
31. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B
Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255
[TBL] [Abstract][Full Text] [Related]
32. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract][Full Text] [Related]
33. A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients.
Yeh YS; Tsai HL; Ma CJ; Wu DC; Lu CY; Wu IC; Hou MF; Wang JY
Chemotherapy; 2012; 58(5):411-8. PubMed ID: 23306825
[TBL] [Abstract][Full Text] [Related]
34. The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver.
Geva R; Shamai S; Brazowsky E; Paoulas M; Ben-Haim M; Johnstone E; Alex B; Shacham-Shmueli E
Cancer Invest; 2015 Apr; 33(4):89-97. PubMed ID: 25723812
[TBL] [Abstract][Full Text] [Related]
35. Association of DNA Repair and Drug Transporter in Relation to Chemosensitivity in Primary Culture of Thai Gastric Cancer Patients.
Wongsirisin P; Limpakan Yamada S; Yodkeeree S; Punfa W; Limtrakul P
Biol Pharm Bull; 2018; 41(3):360-367. PubMed ID: 29491212
[TBL] [Abstract][Full Text] [Related]
36. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
Hoffmann AC; Wild P; Leicht C; Bertz S; Danenberg KD; Danenberg PV; Stöhr R; Stöckle M; Lehmann J; Schuler M; Hartmann A
Neoplasia; 2010 Aug; 12(8):628-36. PubMed ID: 20689757
[TBL] [Abstract][Full Text] [Related]
37. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
38. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
39. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
40. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
